OX40L and CD30L blockade could improve asthma
Study suggests that future asthma therapies should target OX40L and CD30L
Respiratory Disease
An oral option for gastrointestinal problems
Zeposia could help solve the unmet need of more oral drugs for moderate to severe CD and UC patients
Trying to take pediatric brain tumors down a peg
Ziopharm Oncology doses first DIPG patient in Phase 1/2 trial of Controlled IL-12
Looking at the frontrunners
Three compounds are in the spotlight now as new and repurposed drug options are examined for COVID-19
Anti-inflammatory TAT CARMIL1 discovery offers hope for COVID-19
Peptide combination could be effective in reducing damage caused by COVID-19 infections
Galectin Therapeutics begins enrollment in NASH-RX trial
Belapectin has shown ability to prevent the development of esophageal varices in NASH patients
FDA approves Zogenix’s Fintepla for Dravet syndrome
The FDA has approved Fintepla for Dravet syndrome in patients 2 and older
Guest Commentary: Accelerating the pace of pharma innovation at a molecular level
Innovation isn’t just measured in the number of approvals, and looking at NMEs might be a better gauge of the ways in which drug discovery is currently thriving
Investigating an IL-6 antibody
An update on Sanofi and Regeneron’s Kevzara trial in hospitalized COVID-19 patients
Radiation-induced lung injury: Is there finally an approved treatment on the way?
Aqualung Therapeutics receives a $2.3 million award to develop a novel therapeutic antibody for patients with radiation-induced lung injury
